Identification

Name
Sirolimus
Accession Number
DB00877  (APRD00178, DB02439)
Type
Small Molecule
Groups
Approved, Investigational
Description

A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

Structure
Thumb
Synonyms
  • (-)-Rapamycin
  • Rapamycin
  • sirolimús
  • sirolimus
  • sirolimusum
External IDs
AY-22989 / WY-090217
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RapamuneTablet, sugar coated1 mg/1OralWyeth Pharmaceuticals Llc, a Subsidiary of Pfizer Inc.2001-07-01Not applicableUs
RapamuneTablet5 mgOralPfizerNot applicableNot applicableCanada
RapamuneTablet, sugar coated2 mg/1OralWyeth Pharmaceuticals Inc.2006-06-07Not applicableUs
RapamuneTablet, sugar coated1 mg/1OralCardinal Health2001-07-012011-08-31Us
RapamuneTablet, coated2 mgOralPfizer2001-03-13Not applicableEu
RapamuneTablet, coated1 mgOralPfizer2001-03-13Not applicableEu
RapamuneTablet, sugar coated0.5 mg/1OralWyeth Pharmaceuticals Llc, a Subsidiary of Pfizer Inc.2010-03-01Not applicableUs
RapamuneTablet2 mgOralPfizerNot applicableNot applicableCanada
RapamuneTablet, coated0.5 mgOralPfizer2001-03-13Not applicableEu
RapamuneTablet, coated2 mgOralPfizer2001-03-13Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-sirolimusTablet5 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-sirolimusSolution1.0 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-sirolimusTablet2 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Gd-sirolimusTablet1.0 mgOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
SirolimusTablet, film coated1 mg/1OralCadila Healthcare Limited2014-01-072014-01-03Us
SirolimusTablet, sugar coated2 mg/1OralGreenstone, Llc2014-10-27Not applicableUs
SirolimusTablet, sugar coated0.5 mg/1OralGreenstone, Llc2014-01-07Not applicableUs
SirolimusTablet, film coated0.5 mg/1OralCadila Pharnmaceuticals2014-01-15Not applicableUs
SirolimusTablet, film coated0.5 mg/1OralAmerincan Health Packaging2015-03-31Not applicableUs
SirolimusTablet1 mg/1OralAmerican Health Packaging2015-11-05Not applicableUs
Categories
UNII
W36ZG6FT64
CAS number
53123-88-9
Weight
Average: 914.187
Monoisotopic: 913.555141608
Chemical Formula
C51H79NO13
InChI Key
QFJCIRLUMZQUOT-HPLJOQBZSA-N
InChI
InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
IUPAC Name
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0^{4,9}]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
SMILES
[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC

Pharmacology

Indication

For the prophylaxis of organ rejection in patients receiving renal transplants.

Associated Conditions
Pharmacodynamics

Sirolimus, a macrocyclic lactone produced by Streptomyces hygroscopicus, is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients receiving renal transplants. It is recommended that sirolimus be used in a regimen with cyclosporine and corticosteroids.

Mechanism of action

Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.

TargetActionsOrganism
ASerine/threonine-protein kinase mTOR
inhibitor
Human
APeptidyl-prolyl cis-trans isomerase FKBP1A
other
Human
AFibroblast growth factor 2
other/unknown
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

92%

Metabolism
Route of elimination
Not Available
Half life

57-63 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
TOR Signalling Pathway: Rapamycin-Based RepressionSignaling
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of Sirolimus can be decreased when combined with (R)-warfarin.
(S)-WarfarinThe metabolism of Sirolimus can be decreased when combined with (S)-Warfarin.
16-BromoepiandrosteroneThe metabolism of Sirolimus can be decreased when combined with 16-Bromoepiandrosterone.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Sirolimus is combined with 2-Methoxyethanol.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Sirolimus.
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Sirolimus.
3,5-diiodothyropropionic acidThe metabolism of Sirolimus can be decreased when combined with 3,5-diiodothyropropionic acid.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Sirolimus.
5-androstenedioneThe metabolism of Sirolimus can be decreased when combined with 5-androstenedione.
6-Deoxyerythronolide BThe metabolism of Sirolimus can be decreased when combined with 6-Deoxyerythronolide B.
Food Interactions
Not Available

References

Synthesis Reference

Madhup K. Dhaon, Chi-nung Hsiao, Subhash R. Patel, Peter J. Bonk, Sanjay R. Chemburkar, Yong Y. Chen, "One pot synthesis of tetrazole derivatives of sirolimus." U.S. Patent US20080167335, issued July 10, 2008.

US20080167335
General References
  1. Pritchard DI: Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today. 2005 May 15;10(10):688-91. [PubMed:15896681]
  2. Shuchman M: Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med. 2006 Nov 9;355(19):1949-52. [PubMed:17093244]
  3. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005 Aug 15;65(16):7052-8. [PubMed:16103051]
  4. Chan S: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004 Oct 18;91(8):1420-4. [PubMed:15365568]
  5. Graziani EI: Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. Nat Prod Rep. 2009 May;26(5):602-9. doi: 10.1039/b804602f. Epub 2009 Mar 5. [PubMed:19387497]
External Links
Human Metabolome Database
HMDB15015
KEGG Drug
D00753
KEGG Compound
C07909
PubChem Compound
5284616
PubChem Substance
46505675
ChemSpider
10482078
BindingDB
36609
ChEBI
9168
ChEMBL
CHEMBL413
Therapeutic Targets Database
DNC001197
PharmGKB
PA451365
HET
RAP
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sirolimus
ATC Codes
S01XA23 — SirolimusL04AA10 — Sirolimus
AHFS Codes
  • 92:44.00 — Immunosuppressive Agents
PDB Entries
1c9h / 1fap / 1fkb / 1fkl / 1pbk / 1z58 / 2dg3 / 2dg4 / 2dg9 / 2vcd
show 9 more
FDA label
Download (480 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Untreated Adult Acute Myeloid Leukemia1
0CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T-Cell Leukemia/Lymphoma / Burkitt's Lymphoma / Lymphoid Malignancies (New or Relapsed) / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL)1
0CompletedTreatmentInvasive Bladder Cancer Stage II1
0CompletedTreatmentPlasma Cell Myeloma1
0CompletedTreatmentTransplantation, Stem Cell1
0CompletedTreatmentTumors, Solid1
0RecruitingTreatmentBladder Cancers1
0RecruitingTreatmentSickle Cell Disorders1
0TerminatedTreatmentAcute Kidney Injury (AKI) / Renal Transplanted Recipients1
0TerminatedTreatmentPemphigus1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAstrocytomas / Atypical Teratoid/Rhabdoid Tumor / Clear Cell Sarcoma of Soft Tissue / Ependymomas / Ewing's Sarcoma (ES) / Germ Cell Tumors / Gliomas / Hepatoblastomas / Medulloblastomas / Neuroblastomas / Renal Cell Adenocarcinoma / Retinoblastoma / Rhabdoid Tumors / Rhabdomyosarcomas / Sarcoma, Osteogenic / Wilms' tumor1
1Active Not RecruitingTreatmentCancer of Kidney / Cancer of Liver / Malignant Lymphomas / Neoplasms, Breast / Neoplasms, Lung1
1Active Not RecruitingTreatmentCancer, Advanced1
1Active Not RecruitingTreatmentClear Cell Carcinoma / Ewing's Sarcoma (ES) / Gastrointestinal Tumors / Germ Cell Tumors / Hepatic Tumors / Malignant Lymphomas / Melanoma / Neuroblastomas / Non-rhabdomyosarcoma / Renal Cell Adenocarcinoma / Rhabdoid Tumors / Rhabdomyosarcomas / Wilms' tumor1
1Active Not RecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Epithelial Cancer / Stage IIA Primary Peritoneal Cavity Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Epithelial Cancer / Stage IIB Primary Peritoneal Cavity Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Epithelial Cancer / Stage IIC Primary Peritoneal Cavity Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Primary Peritoneal Cavity Cancer1
1Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedNot AvailableAcute Lymphoblastic Leukaemias (ALL)1
1CompletedNot AvailableAdvanced Solid Tumors / Refractory to Standard Therapies1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Sirolimus1
1CompletedBasic ScienceDrug Interactions / High Cholesterol / Immunosuppression / Pharmacokinetics1
1CompletedBasic ScienceSarcopenia1
1CompletedPreventionChronic Renal Failure (CRF) / Immunosuppression / Transplantation, Kidney1
1CompletedPreventionNeoplastic Syndrome / Non-Melanomatous Skin Cancer1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAging / Coronary Artery Disease1
1CompletedTreatmentAllogeneic Stem Cell Transplantation / Malignancies, Hematologic1
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO) / Estrogen Receptor Negative / Estrogen Receptor Positive / Glioblastomas / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Metastatic Renal Cell Cancer / Recurrent Adult Brain Neoplasm / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Hepatocellular Carcinoma / Recurrent Lung Carcinoma / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Prostate Carcinoma / Recurrent Uterine Corpus Carcinoma / Renal Cell Carcinoma Recurrent / Resectable Hepatocellular Carcinoma / Sarcomas / Stage IA Breast Cancer / Stage IA Ovarian Cancer / Stage IA Uterine Corpus Cancer / Stage IB Breast Cancer / Stage IB Ovarian Cancer / Stage IB Uterine Corpus Cancer / Stage IC Ovarian Cancer / Stage II Uterine Corpus Cancer / Stage IIA Breast Cancer / Stage IIA Lung Carcinoma / Stage IIA Ovarian Cancer / Stage IIB Breast Cancer / Stage IIB Esophageal Cancer / Stage IIB Lung Carcinoma / Stage IIB Ovarian Cancer / Stage IIB Skin Melanoma / Stage IIC Ovarian Cancer / Stage IIC Skin Melanoma / Stage IIIA Breast Cancer / Stage IIIA Esophageal Cancer / Stage IIIA Lung Carcinoma / Stage IIIA Ovarian Cancer / Stage IIIA Skin Melanoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Breast Cancer / Stage IIIB Esophageal Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Skin Melanoma / Stage IIIB Uterine Corpus Cancer / Stage IIIC Breast Cancer / Stage IIIC Esophageal Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Skin Melanoma / Stage IIIC Uterine Corpus Cancer / Stage IV Bladder Urothelial Carcinoma / Stage IV Esophageal Cancer / Stage IV Ovarian Cancer / Stage IV Prostate Cancer / Stage IV Skin Melanoma / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1CompletedTreatmentAnterior Uveitis (AU)1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentCML / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Myeloid Leukemias1
1CompletedTreatmentCancer, Advanced4
1CompletedTreatmentCancer, Advanced / Metastatic Cancers1
1CompletedTreatmentChildhood Solid Tumors / Malignant Solid Tumours1
1CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1CompletedTreatmentDiabetic Macular Edema (DME) / Retinopathy, Diabetic1
1CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentFacial Angiofibroma1
1CompletedTreatmentGlioblastomas1
1CompletedTreatmentGraft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Transplantation, Homologous1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHepatic Complications1
1CompletedTreatmentHepatocellular,Carcinoma / Rapamycin1
1CompletedTreatmentKidney Diseases1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Plasma Cell Neoplasms1
1CompletedTreatmentLiver Cancer1
1CompletedTreatmentLow-Grade Gliomas1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1CompletedTreatmentNeoplasms Metastasis / Tumors1
1CompletedTreatmentPachyonychia Congenita1
1CompletedTreatmentDiffuse posterior uveitis / Panuveitis / Uveitis / Uveitis, Intermediate1
1CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1CompletedTreatmentRejection, Transplant / Transplantation, Renal1
1CompletedTreatmentSarcomas1
1CompletedTreatmentTumors, Central Nervous System / Tumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Not Yet RecruitingSupportive CareHematopoietic and Lymphoid Cell Neoplasm / Hematopoietic Cell Transplantation Recipient1
1RecruitingBasic ScienceAging1
1RecruitingTreatmentAdvanced Solid Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentGraft Versus Host Disease (GVHD) / Sickle Cell Disorders1
1RecruitingTreatmentPompe's Disease1
1RecruitingTreatmentRenal Transplanted Recipients / Transplantation, Kidney / Transplantation, Renal1
1RecruitingTreatmentSickle Cell Disorders1
1RecruitingTreatmentSickle Cell-thalassemia Disease / Thalassaemic disorders1
1SuspendedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedPreventionAdult Hodgkin Lymphoma / Adult Myelodysplastic Syndrome / Agnogenic Myeloid Metaplasia / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Hodgkin Lymphoma / Childhood Myelodysplastic Syndrome / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Non-Hodgkin's lymphoma1
1TerminatedTreatmentAdvanced Solid Cancers1
1TerminatedTreatmentEosinophilic Gastroenteritis / Oesophagitis, Eosinophilic1
1TerminatedTreatmentLeukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Smith-Magenis Syndrome1
1TerminatedTreatmentLeukemias / Malignant Lymphomas1
1TerminatedTreatmentLeukemias / Malignant Lymphomas / Plasma Cell Myeloma1
1TerminatedTreatmentTumors1
1Unknown StatusTreatmentCardiac Hypertrophy / Immunosuppression1
1Unknown StatusTreatmentRefractory Solid Tumors in Children1
1WithdrawnSupportive CareAcute myeloid leukaemia (in remission) / Acute, secondary Myeloid Leukemia / Primary Myelofibrosis / Primary Myelofibrosis, Prefibrotic Stage / Secondary Myelofibrosis1
1WithdrawnTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1WithdrawnTreatmentNon-Small Cell Lung Cancer Recurrent / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentNon-Small Cell Lung Cancer Recurrent / Unspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
1, 2Active Not RecruitingTreatmentAlemtuzumab (Campath ) / Graft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Sickle Cell Disorders / Sirolimus (Rapamune )1
1, 2Active Not RecruitingTreatmentAnemia, Hemolytic, Autoimmune / Autoimmune Lymphoproliferative Syndrome (ALPS) / Autoimmune Neutropenia / Autoimmune Pancytopenia / Evans Syndrome / Idiopathic Thrombocytopenic Purpura (ITP) / Inflammatory Bowel Diseases (IBD) / Lupus Erythematosus, Systemic / Rheumatoid Arthritis1
1, 2Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1, 2Active Not RecruitingTreatmentRectum Cancer1
1, 2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentAdvanced Soft Tissue Sarcoma1
1, 2CompletedTreatmentAge-Related Macular Degeneration (ARMD)1
1, 2CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Dry Macular Degeneration1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentCNI Side Effects1
1, 2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD)1
1, 2CompletedTreatmentInfection, Human Immunodeficiency Virus I1
1, 2CompletedTreatmentKidney Diseases / Renal Failure / Transplantation, Kidney1
1, 2CompletedTreatmentKidney Diseases / Transplantation, Kidney1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentMalignancies, Hematologic / Multiple Myeloma (MM)1
1, 2CompletedTreatmentMalignant Peripheral Nerve Sheath Tumour (MPNST) / Sarcomas1
1, 2CompletedTreatmentMetastatic Bladder Cancer / Recurrent Bladder Carcinoma / Stage II Bladder Cancer / Stage III Bladder Cancer1
1, 2CompletedTreatmentMouth Neoplasms / Neoplasms, Head and Neck / Squamous Cell Carcinoma (SCC) / Tongue Neoplasms1
1, 2CompletedTreatmentPolycystic Kidney Diseases1
1, 2CompletedTreatmentRetinopathy, Diabetic1
1, 2CompletedTreatmentScleritis1
1, 2CompletedTreatmentSclerosis, Progressive Systemic1
1, 2Not Yet RecruitingPreventionAcute GvHD / Graft Versus Host Disease (GVHD)1
1, 2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Chronic Myelomonocytic Leukemia / Myeloproliferative Neoplasm, Unclassifiable1
1, 2RecruitingPreventionGraft Versus Host Disease (GVHD) / Lung Cancers1
1, 2RecruitingTreatmentActivated PI3K-delta Syndrome / Congenital Immunodeficiency1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / CD45-Positive Neoplastic Cells Present / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome With Excess Blasts / Recurrent Adult Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia1
1, 2RecruitingTreatmentAdenocarcinoma of the Lung / Extensive Stage Small Cell Lung Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Recurrent Small Cell Lung Carcinoma / Squamous Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1, 2RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Carcinoma Metastatic in the Bone / PSA Level Greater Than or Equal to Two / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer / Stage IV Prostate Cancer AJCC v71
1, 2RecruitingTreatmentDermal Atrophy1
1, 2RecruitingTreatmentDesmoid Tumors1
1, 2RecruitingTreatmentHematopoietic Stem Cell Transplantation (HSCT) / Multiple Myeloma (MM)1
1, 2RecruitingTreatmentMalignancies, Hematologic1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentMalignant Peripheral Nerve Sheath Tumour (MPNST) / Sarcomas1
1, 2RecruitingTreatmentSickle Cell Disorders2
1, 2TerminatedTreatmentAge-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization1
1, 2TerminatedTreatmentDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia1
1, 2TerminatedTreatmentDisseminated Sclerosis / Relapsing Remitting Multiple Sclerosis (RRMS)1
1, 2TerminatedTreatmentGraft Versus Host Disease (GVHD)1
1, 2TerminatedTreatmentMultiple Myeloma (MM)1
1, 2Unknown StatusTreatmentAplastic Anaemia (AA)1
1, 2Unknown StatusTreatmentEnd-Stage Renal Disease (ESRD) / Renal Failure1
1, 2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
1, 2WithdrawnTreatmentHyperinsulinism1
1, 2WithdrawnTreatmentLung Cancers1
1, 2WithdrawnTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma1
2Active Not RecruitingOtherDepression1
2Active Not RecruitingPreventionAcute Leukemia in Remission / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Primary Myelofibrosis1
2Active Not RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentAcute GvHD1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute, secondary Myeloid Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia in Remission / Secondary Myelodysplastic Syndromes / Therapy-Related Myelodysplastic Syndrome1
2Active Not RecruitingTreatmentCapillary Lymphatic Arterial Venous Malformations / Capillary Venous Lymphatic Malformation / Kaposiform Hemangioendotheliomas / Lymphangiectasia Syndromes / Microcystic Lymphatic Malformation / Mucocutaneous Lymphangiomatosis and Thrombocytopenia / PTEN Overgrowth Syndrome With Vascular Anomaly / Tufted Angioma / Venous Lymphatic Malformation1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Low-Grade / Mantle Cell Lymphoma (MCL) / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentEpidermolysis Bullosa Simplex / Epidermolysis Bullosa Simplex Kobner / Weber-Cockayne Syndrome1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)2
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myeloproliferative Disorders1
2Active Not RecruitingTreatmentRelapsed / Recurrent Germ Cell Tumors1
2Active Not RecruitingTreatmentSickle Cell Disorders2
2Active Not RecruitingTreatmentVascular Malformations1
2CompletedNot AvailableSturge - Weber Syndrome (SWS)1
2CompletedPreventionAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Chronic myelogenous leukemia / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2CompletedPreventionAcute Lymphoblastic Leukaemias (ALL) / Hodgkins Disease (HD) / Malignancies, Hematologic / Myelodysplastic Syndrome / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)1
2CompletedPreventionBlood and Marrow Transplant (BMT) / Leukemias / Non-Hodgkin's Lymphoma (NHL)1
2CompletedPreventionChronic Renal Failure (CRF) / Immunosuppression / Transplantation, Kidney1
2CompletedPreventionDiabetes, Diabetes Mellitus Type 11
2CompletedPreventionGraft Versus Host Disease, Acute1
2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions / Secondary Myelofibrosis / Small Intestine Cancer1
2CompletedSupportive CareGraft Versus Host Disease (GVHD)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3- / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Lymphoma / Childhood Myelodysplastic Syndrome / Chronic Lymphocytic Leukemia (CLL) - Refractory / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Burkitt Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Plasma Cell Myeloma / Secondary Myelodysplastic Syndromes / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Burkitt Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Contiguous Immunoblastic Lymphoma / Stage II Adult Non-Contiguous Immunoblastic Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Burkitt Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Burkitt Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma / Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Burkitt Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Burkitt Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Burkitt Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
2CompletedTreatmentAge-Related Macular Degeneration (ARMD)1
2CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization1
2CompletedTreatmentAngiofibromas / Tuberous Sclerosis1
2CompletedTreatmentAplastic Anaemia (AA) / Severe Aplastic Anemia (SAA)1
2CompletedTreatmentAutism, Early Infantile / Self-injury / Tuberous Sclerosis Complex (TSC)1
2CompletedTreatmentBlood and Marrow Transplant (BMT) / Graft Versus Host Disease (GVHD)1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancers / Leukemias / Malignant Lymphomas1
2CompletedTreatmentCowden's Disease / Hamartoma Syndrome, Multiple1
2CompletedTreatmentDiabetes Mellitus, Insulin-Dependent1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia / Metabolic Diseases1
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentDisorder Related to Renal Transplantation1
2CompletedTreatmentEngraftment Syndrome / Graft Versus Host Disease (GVHD) / Renal Cell Adenocarcinoma1
2CompletedTreatmentExudative Age Related Macular Degeneration1
2CompletedTreatmentEye Dryness1
2CompletedTreatmentGenetics / Growth Disorders / PIK3CA-Related Overgrowth Spectrum (PROS)1
2CompletedTreatmentGlioblastomas / Gliosarcoma1
2CompletedTreatmentGlomerulonephritis, Membranous / Lupus Membranous Nepropathy1
2CompletedTreatmentGlomerulosclerosis, Focal Segmental1
2CompletedTreatmentGraft Versus Host Disease (GVHD)1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignancies, Hematologic1
2CompletedTreatmentH1N1 Pneumonia / Hypoxemia1
2CompletedTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentHodgkins Disease (HD) / Leukaemia, Lymphoblastic / Multiple Myeloma (MM) / Myelogenous Leukemia / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentKidney, Polycystic1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
2CompletedTreatmentLymphangioleiomyomatosis / Tuberous Sclerosis1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentNeurofibromatosis 21
2CompletedTreatmentNeurofibromatosis Type 11
2CompletedTreatmentRecurrent Implantation Failure (RIF)1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2CompletedTreatmentRenal Failure1
2CompletedTreatmentSarcoma, Osteogenic1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSegmental Overgrowth Disorders Due to PIK3CA1
2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
2CompletedTreatmentTransplantation, Kidney3
2Not Yet RecruitingTreatmentLymphatic Malformations / Pediatric1
2Not Yet RecruitingTreatmentMalignant Peripheral Nerve Sheath Tumour (MPNST) / Neurofibromatosis 11
2Not Yet RecruitingTreatmentOvarian Serous Tumor / Recurrent Ovarian Carcinoma1
2Not Yet RecruitingTreatmentSclerosis, Progressive Systemic1
2RecruitingBasic ScienceAging1
2RecruitingBasic ScienceCancer of the Breast1
2RecruitingBasic ScienceAcute, secondary Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2RecruitingPreventionEnd Stage Renal Disease (ESRD) / Venous Stenosis1
2RecruitingPreventionGraft Versus Host Disease (GVHD)1
2RecruitingPreventionGraft Versus Host Disease (GVHD) / Haematological Malignancies1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma / Acute Myelogenous Leukaemia (AML) / Acute Undifferentiated Leukemia (AUL) / Chemotherapy-sensitive Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic, recurrent Lymphocytic Leukemia / Hematopoietic Cell Transplantation Recipient / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Prolymphocytic / Loss of Chromosome 17p / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Recurrent Waldenstrom Macroglobulinemia / T-cell chronic lymphocytic leukaemia1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myeloid Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphoblastic Leukemia/Lymphoma / Biphenotypic/Undifferentiated/Prolymphocytic Leukemias / Bone Marrow Failure Syndromes / Burkitt's Lymphoma / Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia or MDS in Aplasia / Leukemia, Acute / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, Hodgkins / Lymphoma, Large-Cell / Lymphoplasmacytic Lymphoma / Mantle Cell Lymphoma (MCL) / Marginal Zone B-Cell Lymphoma / MRD Positive Leukemia / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms/Myelofibrosis / Myeloproliferative Syndromes / Natural Killer Cell Malignancies / Recurrent Cutaneous T-cell lymphoma / Relapsed Chronic Lymphocytic Leukemia / Relapsed Multiple Myeloma / Relapsed Small Lymphocytic Lymphoma / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentAdenomatous Polyposis Coli1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Adult Myelodysplastic Syndrome / Adult Non-Hodgkin's Lymphoma / Aggressive Non-Hodgkin Lymphoma / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Diffuse Large B -Cell Lymphoma / Childhood Diffuse Large B-Cell Lymphoma / Childhood Myelodysplastic Syndrome / Childhood Non-Hodgkin's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia (CLL) - Refractory / Chronic Lymphocytic Leukemia in Remission / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic, recurrent Lymphocytic Leukemia / Hematopoietic and Lymphoid Cell Neoplasm / Leukemia, Prolymphocytic / Mantle Cell Lymphoma (MCL) / Plasma Cell Myeloma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia / Waldenström's Macroglobulinemia (WM)1
2RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia1
2RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2RecruitingTreatmentAngiofibroma of Face / Tuberous Sclerosis1
2RecruitingTreatmentAplastic Anaemia (AA) / Immunodeficiency Syndrome / Non-Cancer Diagnosis / Severe Aplastic Anemia (SAA)1
2RecruitingTreatmentArteriovenous Malformations / Arteriovenous Malformations (Stage II to IV)1
2RecruitingTreatmentCancers1
2RecruitingTreatmentChondrosarcoma, Mesenchymal / Conventional Chondrosarcoma / Dedifferentiated Chondrosarcoma / Myxoid Liposarcoma1
2RecruitingTreatmentDiabetes, Diabetes Mellitus Type 12
2RecruitingTreatmentEpidermolysis Bullosa Simplex / Epidermolysis Bullosa Simplex Kobner / Weber-Cockayne Syndrome1
2RecruitingTreatmentGraft Versus Host Disease (GVHD) / Sickle Cell Disorders / Thalassaemic disorders / Transplantation, Stem Cell1
2RecruitingTreatmentHHV-8 / Human Immunodeficiency Virus (HIV) / Lymphoproliferative Disorders / Malignancies1
2RecruitingTreatmentHaemangioma-thrombocytopenia syndrome / Kaposiform Hemangioendothelioma (KHE) / Tufted Angioma1
2RecruitingTreatmentIn-stent Stenosis / Peripheral Pulmonary Stenosis1
2RecruitingTreatmentKaposiform Hemangioendothelioma / Kasabach Merritt Phenomenon1
2RecruitingTreatmentLymphangioleiomyomatosis1
2RecruitingTreatmentMetastatic Medullary Thyroid Cancer1
2RecruitingTreatmentMultiple System Atrophy (MSA)1
2RecruitingTreatmentPinealoblastoma1
2RecruitingTreatmentPure Red Cell Aplasia / Red Blood Cell Disorder / Sickle Cell Disorders / Stem Cell Transplant Complications1
2RecruitingTreatmentRecurrent Neuroblastoma1
2RecruitingTreatmentRefractory and/or Relapsed Metastatic Solid Tumors1
2RecruitingTreatmentSevere Aplastic Anemia (SAA)1
2RecruitingTreatmentSickle Cell Disorders2
2TerminatedPreventionAcute Leukemia in Remission / Leukemia, Myeloid, Accelerated-Phase / Leukemia, Myeloid, Chronic-Phase / Myelodysplastic Syndromes1
2TerminatedPreventionGraft Versus Host Disease (GVHD)1
2TerminatedSupportive CareChronic Graft Versus Host Disease / Oral Mucosal Disease Due to Graft-versus-host Disease1
2TerminatedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2TerminatedTreatmentAge-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization1
2TerminatedTreatmentDiabetes, Diabetes Mellitus Type 11
2TerminatedTreatmentDry Macular Degeneration1
2TerminatedTreatmentEnd-Stage Renal Disease (ESRD)1
2TerminatedTreatmentHaematological Malignancies / Leukemias / Malignant Lymphomas / Myelodysplastic Syndrome1
2TerminatedTreatmentHematologic Diseases1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentSarcomas1
2TerminatedTreatmentSquamous Cell Skin Carcinoma1
2TerminatedTreatmentTransplant, Kidney1
2Unknown StatusPreventionAcute Graft-Versus-Host Disease / Chronic Graft Versus Host Disease / Steroid Refractory Graft-Versus-Host Disease1
2Unknown StatusTreatmentLymphangioleiomyomatosis / Tuberous Sclerosis1
2Unknown StatusTreatmentNonmalignant Neoplasm1
2Unknown StatusTreatmentTransplantation, Liver1
2WithdrawnPreventionHematopoietic Stem Cell Transplant (HSCT) / Severe Combined Immunodeficiency / Transplacental Maternal Engraftment1
2WithdrawnTreatmentCutaneous T-Cell Lymphoma (CTCL)1
2WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
2, 3Active Not RecruitingTreatmentChronic Graft Versus Host Disease1
2, 3Active Not RecruitingTreatmentInclusion Body Myositis (IBM)1
2, 3Active Not RecruitingTreatmentTransplantation, Kidney1
2, 3CompletedTreatmentHepatocellular,Carcinoma1
2, 3Not Yet RecruitingTreatmentTransplantation, Liver1
2, 3RecruitingTreatmentCongenital Hypoplastic Anemia1
2, 3RecruitingTreatmentLiver Diseases1
2, 3RecruitingTreatmentSturge-Weber Syndrome1
2, 3TerminatedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)2
2, 3TerminatedTreatmentHigh Blood Pressure (Hypertension)1
2, 3Unknown StatusTreatmentPolycystic Kidney Diseases1
2, 3WithdrawnTreatmentProstate Cancer1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Graft Versus Host Disease (GVHD) / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
3CompletedNot AvailableGraft Versus Host Disease (GVHD) / Transplantation, Kidney1
3CompletedPreventionGraft Versus Host Disease (GVHD) / Survival1
3CompletedPreventionKidney Diseases1
3CompletedPreventionRenal Allograft Recipients1
3CompletedPreventionTransplant, Kidney1
3CompletedPreventionTransplantation, Renal1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia (CLL) - Refractory / Chronic, recurrent Lymphocytic Leukemia / Hematopoietic and Lymphoid Cell Neoplasm / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Prolymphocytic / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Plasma Cell Myeloma / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Hodgkin Lymphoma / Small Lymphocytic Lymphoma (SLL) / T-cell chronic lymphocytic leukaemia / Waldenström's Macroglobulinemia (WM)1
3CompletedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3CompletedTreatmentBirt-Hogg-Dubé Syndrome1
3CompletedTreatmentCardiovascular Abnormalities1
3CompletedTreatmentChronic Myeloid Leukemia (CML) / Leukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Myelodysplastic Syndromes1
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
3CompletedTreatmentEnd Stage Liver Diseases / Impaired Renal Function1
3CompletedTreatmentFacial Angiofibroma1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Renal Failure1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Transplantation, Kidney1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentNon-Infectious Uveitis of the Posterior Segment of the Eye1
3CompletedTreatmentSkin Cancers / Transplantation, Kidney1
3CompletedTreatmentTransplantation, Kidney1
3CompletedTreatmentTransplantation, Renal2
3CompletedTreatmentUvea; Posterior, Disorder / Uveitis; Posterior, Disorder1
3Not Yet RecruitingTreatmentBladder Cancers1
3RecruitingPreventionArteriovenous Fistulas / Chronic Renal Failure (CRF) / Complication of Hemodialysis / Complication of Renal Dialysis / End Stage Kidney Disease / End Stage Renal Disease (ESRD) / ESRD / Vascular Access Complications1
3RecruitingTreatmentDyspnea / LAM / Lymphangioleiomyomatosis1
3RecruitingTreatmentPolycystic Kidney, Type 1 Autosomal Dominant Disease / Polycystic Kidney, Type 2 Autosomal Dominant Disease1
3RecruitingTreatmentVascular Malformations1
3TerminatedTreatmentAtherosclerosis / Renal Failure1
3TerminatedTreatmentEnd-Stage Renal Disease (ESRD) / Transplantation, Kidney1
3TerminatedTreatmentOral Lichen Planus1
3TerminatedTreatmentTransplant, Kidney1
3TerminatedTreatmentTransplantation, Liver1
3Unknown StatusPreventionHepatocellular,Carcinoma1
3Unknown StatusPreventionTransplantation, Kidney1
3Unknown StatusTreatmentLymphangioleiomyomatosis1
4Active Not RecruitingPreventionKidney Transplant Rejection1
4Active Not RecruitingTreatmentPancreas Transplantation / Transplantation, Kidney1
4CompletedNot AvailableChronic Renal Failure (CRF) / Graft Versus Host Disease (GVHD) / Transplantation, Kidney1
4CompletedNot AvailableFunction of Renal Transplant1
4CompletedHealth Services ResearchCoronary Artery Restenosis / Coronary Heart Disease (CHD)1
4CompletedPreventionAcute Graft Rejection / Delayed Graft Function1
4CompletedPreventionHepatitis C Viral Infection1
4CompletedPreventionRejection, Transplant / Renal Allograft Recipients / Transplant, Kidney1
4CompletedPreventionRejection, Transplant / Renal Failure1
4CompletedPreventionSkin Neoplasms / Transplantation, Kidney1
4CompletedPreventionTransplantation, Kidney2
4CompletedTreatmentAdult Primary Kidney Transplantation1
4CompletedTreatmentAgeing / Rejection, Transplant / Renal Failure1
4CompletedTreatmentChronic Kidney Disease (CKD) / Transplantation, Kidney1
4CompletedTreatmentComparative Study / Immunosuppressive Agents1
4CompletedTreatmentCoronary Artery Restenosis1
4CompletedTreatmentDisorder Related to Renal Transplantation / Infections, Cytomegalovirus1
4CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
4CompletedTreatmentGraft Versus Host Disease (GVHD) / Renal Failure2
4CompletedTreatmentInflammatory Reaction1
4CompletedTreatmentKidney Diseases1
4CompletedTreatmentKidney Diseases / Renal Failure1
4CompletedTreatmentPrimary Renal Allograft1
4CompletedTreatmentRejection, Transplant / Renal Failure / Transplant, Kidney1
4CompletedTreatmentRejection, Transplant / Renal Failure / Transplantation, Kidney1
4CompletedTreatmentRenal Angiomyolipomas1
4CompletedTreatmentTransplant, Kidney3
4CompletedTreatmentTransplantation, Kidney6
4CompletedTreatmentTransplantation, Liver1
4CompletedTreatmentTransplantation, Renal1
4RecruitingPreventionInfections, Cytomegalovirus1
4RecruitingPreventionKidney Transplant Infection1
4RecruitingTreatmentCCR5 / HIV Reservoir / Human Immunodeficiency Virus (HIV) / Transplant, Kidney1
4RecruitingTreatmentConnective Tissue Diseases / Thrombocytopenias1
4RecruitingTreatmentCrohn's Disease (CD)1
4RecruitingTreatmentPure Red Cell Aplasia1
4RecruitingTreatmentRefractory Solid Tumors1
4RecruitingTreatmentTransplantation, Kidney1
4RecruitingTreatmentUterine Leiomyomas1
4TerminatedPreventionRenal Transplant Patients at High-risk for Skin Cancer1
4TerminatedPreventionSkin Cancers / Transplantation, Kidney1
4TerminatedTreatmentDelayed Graft Function / Slow Graft Function-defined at Creatinine >= 3.0 by Post-op Day 5 Without Requiring Dialysis / Transplant, Kidney1
4TerminatedTreatmentKidney Transplant Failure and Rejection1
4Unknown StatusPreventionImmunosuppression / Transplantation, Kidney / Transplantations2
4Unknown StatusTreatmentChronic Allograft Nephropathy (CAN) / Glomerular Filtration Rate (GFR)1
4Unknown StatusTreatmentChronic Renal Failure (CRF) / Immunosuppression / Interstitial Fibrosis (IF) / Transplantations1
4Unknown StatusTreatmentEnd Stage Renal Disease (ESRD) / Transplantation, Kidney1
4Unknown StatusTreatmentKidney Diseases / Rejection, Transplant1
4Unknown StatusTreatmentTransplant, Kidney1
4Unknown StatusTreatmentTransplantation, Kidney2
4WithdrawnNot AvailableTransplantation, Kidney1
4WithdrawnTreatmentKidney Graft Dysfunction1
4WithdrawnTreatmentLiving Donor Kidney Transplants Patients1
Not AvailableActive Not RecruitingPreventionRenal Failure1
Not AvailableActive Not RecruitingTreatmentDiffuse Parenchymal Lung Diseases / Idiopathic Pulmonary Fibrosis (IPF) / Interstitial Lung Disease (ILD)1
Not AvailableCompletedNot AvailableAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
Not AvailableCompletedNot AvailableDiabetes, Diabetes Mellitus Type 1 / Islet Transplantation1
Not AvailableCompletedNot AvailableImmune Thrombocytopenia1
Not AvailableCompletedNot AvailableImmune Thrombocytopenic Purpura ( ITP )1
Not AvailableCompletedNot AvailableTransplantation, Kidney1
Not AvailableCompletedNot AvailableTransplantation, Renal1
Not AvailableCompletedNot AvailableTransplantations1
Not AvailableCompletedPreventionAbsence; Kidney1
Not AvailableCompletedPreventionBK Nephropathy / BK Viremia1
Not AvailableCompletedPreventionTransplant, Kidney2
Not AvailableCompletedScreeningTransplantation, Kidney1
Not AvailableCompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease (ESRD)1
Not AvailableCompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
Not AvailableCompletedTreatmentPosttraumatic Stress Disorders1
Not AvailableCompletedTreatmentTumors, Solid1
Not AvailableNo Longer AvailableNot AvailableDiabetes, Diabetes Mellitus Type 12
Not AvailableNot Yet RecruitingTreatmentHeart Transplantation1
Not AvailableRecruitingNot AvailableLymphangioleiomyomatosis1
Not AvailableRecruitingDiagnosticAcute Rejection of Liver Transplant / Effects of Immunosuppressant Therapy1
Not AvailableRecruitingSupportive CarePrimary Myelofibrosis / Secondary Myelofibrosis1
Not AvailableRecruitingTreatmentBlasts 10 Percent or More of Bone Marrow Nucleated Cells / Chronic Myelomonocytic Leukemia-2 / High Grade Malignant Neoplasm / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts-2 / Myeloid Neoplasm / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders1
Not AvailableTerminatedNot AvailableTransplantation, Renal1
Not AvailableTerminatedTreatmentLymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory / Recurrent Adult Lymphoblastic Lymphoma / Refractory Acute Lymphoblastic Leukemia / Relapsed Lymphoblastic Leukemia1
Not AvailableTerminatedTreatmentPolycystic Liver Disease (PLD)1
Not AvailableTerminatedTreatmentPort-wine Stains (PWS)1
Not AvailableUnknown StatusNot AvailableAcute Rejection of Renal Transplant1
Not AvailableUnknown StatusTreatmentProstate Cancer1
Not AvailableWithdrawnPreventionCardiac Allograft Vasculopathy1

Pharmacoeconomics

Manufacturers
  • Wyeth pharmaceuticals inc
Packagers
  • Cardinal Health
  • Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.
  • Lake Erie Medical and Surgical Supply
  • Patheon Inc.
  • Poli Industria Chimica SPA
  • Wyeth Pharmaceuticals
Dosage forms
FormRouteStrength
SolutionOral1 mg/ml
TabletOral1.0 mg
TabletOral2 mg
TabletOral5 mg
Tablet, coatedOral0.5 mg
Tablet, coatedOral1 mg
Tablet, coatedOral2 mg
Tablet, sugar coatedOral1 mg/1
SolutionOral1.0 mg
SolutionOral1 mg/1mL
TabletOral1 mg/1
TabletOral2 mg/1
Tablet, film coatedOral0.5 mg/1
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral2 mg/1
Tablet, sugar coatedOral0.5 mg/1
Tablet, sugar coatedOral2 mg/1
Prices
Unit descriptionCostUnit
Rapamune 2 mg tablet20.59USD tablet
Rapamune 1 mg/ml Solution12.19USD ml
Rapamune 1 mg tablet11.95USD tablet
Rapamune 0.5 mg tablet5.86USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5212155No1993-05-182010-05-18Us
CA2293793No2006-07-112018-06-11Canada
CA2103571No2003-04-292012-02-21Canada
US5989591Yes1998-09-112018-09-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00173 mg/mLALOGPS
logP4.85ALOGPS
logP7.45ChemAxon
logS-5.7ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area195.43 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity250.66 m3·mol-1ChemAxon
Polarizability101.74 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7841
Blood Brain Barrier-0.9599
Caco-2 permeable-0.6341
P-glycoprotein substrateSubstrate0.8052
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8021
Renal organic cation transporterNon-inhibitor0.8116
CYP450 2C9 substrateNon-substrate0.878
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7776
CYP450 1A2 substrateNon-inhibitor0.9007
CYP450 2C9 inhibitorNon-inhibitor0.9125
CYP450 2D6 inhibitorNon-inhibitor0.9414
CYP450 2C19 inhibitorNon-inhibitor0.9158
CYP450 3A4 inhibitorNon-inhibitor0.9333
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9742
Ames testNon AMES toxic0.6617
CarcinogenicityNon-carcinogens0.9546
BiodegradationNot ready biodegradable0.9593
Rat acute toxicity2.8689 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9831
hERG inhibition (predictor II)Non-inhibitor0.8443
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolide lactams
Sub Class
Not Available
Direct Parent
Macrolide lactams
Alternative Parents
Alpha amino acid esters / Macrolides and analogues / Cyclohexanols / Piperidines / Oxanes / Tertiary carboxylic acid amides / Carboxylic acid esters / Cyclic alcohols and derivatives / Cyclic ketones / Hemiacetals
show 10 more
Substituents
Macrolide lactam / Alpha-amino acid ester / Macrolide / Alpha-amino acid or derivatives / Cyclohexanol / Oxane / Piperidine / Cyclic alcohol / Tertiary carboxylic acid amide / Cyclic ketone
show 24 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
cyclic ketone, antibiotic antifungal drug, organic heterotricyclic compound, secondary alcohol, ether, lactam, macrolide, cyclic acetal (CHEBI:9168) / Plyenes (C07909)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Tfiiic-class transcription factor binding
Specific Function
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly...
Gene Name
MTOR
Uniprot ID
P42345
Uniprot Name
Serine/threonine-protein kinase mTOR
Molecular Weight
288889.05 Da
References
  1. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N: Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010 Mar;1804(3):433-9. doi: 10.1016/j.bbapap.2009.12.001. Epub 2009 Dec 11. [PubMed:20005306]
  2. Shuuin T, Karashima H: [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma]. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. [PubMed:19620795]
  3. Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S. [PubMed:12742462]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Other
General Function
Type i transforming growth factor beta receptor binding
Specific Function
Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruites SMAD7 to ACVR1B which prevent...
Gene Name
FKBP1A
Uniprot ID
P62942
Uniprot Name
Peptidyl-prolyl cis-trans isomerase FKBP1A
Molecular Weight
11950.665 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S. [PubMed:12742462]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Other/unknown
General Function
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name
FGF2
Uniprot ID
P09038
Uniprot Name
Fibroblast growth factor 2
Molecular Weight
30769.715 Da
References
  1. Sehgal SN: Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S. [PubMed:12742462]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764]
  2. Wacher VJ, Silverman JA, Wong S, Tran-Tau P, Chan AO, Chai A, Yu XQ, O'Mahony D, Ramtoola Z: Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. J Pharmacol Exp Ther. 2002 Oct;303(1):308-13. [PubMed:12235265]
  3. Arceci RJ, Stieglitz K, Bierer BE: Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood. 1992 Sep 15;80(6):1528-36. [PubMed:1381629]
  4. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Fehrenbach T, Cui Y, Faulstich H, Keppler D: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):415-20. Epub 2003 Oct 3. [PubMed:14530907]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Monovalent cation:proton antiporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
Gene Name
SLC47A1
Uniprot ID
Q96FL8
Uniprot Name
Multidrug and toxin extrusion protein 1
Molecular Weight
61921.585 Da
References
  1. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB: Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005. doi: 10.1152/ajprenal.00431.2009. Epub 2010 Jan 6. [PubMed:20053795]

Drug created on June 13, 2005 07:24 / Updated on October 16, 2018 08:31